Budget Impact Analysis Shows Revumenib Cost-Neutral for Health Plans Despite High Specialty Drug Costs
- A recent budget impact analysis demonstrates that revumenib (Revuforj) for relapsed/refractory acute leukemias with KMT2A translocation would be cost-neutral for health plans over three years.
- The cost neutrality is primarily driven by revumenib's oral administration, which eliminates expensive infusion-related costs including chair time and administration fees.
- The analysis highlights challenges in evaluating rare disease treatments affecting only 1.7 individuals per million patients, where traditional cost-effectiveness methods may not adequately capture therapeutic value.
- Patient adherence to the oral therapy remains a critical variable that could influence long-term cost-effectiveness and clinical outcomes.
